Weekly Digest – October 2025 Weekly Digest – October 2025 30 September 2025: AbbVie submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) an investigational ADC to treat rare cancer with limited treatment options AbbVie has submitted […]
Weekly Digest – October 2025 Weekly Digest – October 2025 01 October 2025: Enhertu followed by THP supplemental biologics license application accepted in the U.S. for patients with high-risk HER2 positive early-stage breast cancer prior to surgery The U.S. FDA […]
Weekly Digest – October 2025 Weekly Digest – October 2025 30 September 2025: Henlius receives the NMPA IND approval for Its PD-L1 targeting ADC HLX43 in combination with novel anti-EGFR mAb HLX07 The China NMPA approved Henlius’ IND application for […]
Weekly Digest – October 2025 Weekly Digest – October 2025 29 September 2025: Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase 3 trial in patients with high-risk early breast cancer […]
Weekly Digest – October 2025 Weekly Digest – October 2025 30 September 2025: Starpharma announces a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset Starpharma signed a research and option agreement with Radiopharm Theranostics after […]
Weekly Digest – October 2025 Weekly Digest – October 2025 30 September 2025: Debiopharm licenses SunRock Biopharma’s anti-HER3/HER2 antibody to explore the full potential of bispecific ADC Debio 2512 Debiopharm licensed SunRock Biopharma’s bispecific HER3/HER2 antibody SRB21 to develop a […]
